Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raptor Pharmaceuticals has announced that its clinical development division, Bennu Pharmaceuticals, has acquired a clinical product candidate, EC Cysteamine. Bennu has received the exclusive worldwide license of the product by way of its acquisition by merger of Encode Pharmaceuticals.
Subscribe to our email newsletter
With its acquisition of Encode, Bennu has obtained intellectual property rights related to EC Cysteamine, including an exclusive worldwide license to develop and market a product which has received orphan status.
EC Cysteamine is a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA. Cysteamine bitartrate is prescribed for the management of the genetic disorder known as nephropathic cystinosis.
Christopher Starr, Raptor’s CEO, said: “EC Cysteamine will add value, and balance our clinical portfolio with an advanced clinical program focused on a safe and potentially more effective second-generation, proprietary treatment for the management of cystinosis. We plan to continue evaluating EC Cysteamine in other disorders for which it has already shown promise in the clinic.”